NLS drug-2

Elicera Therapeutics has received approval from the Swedish Medical Products Agency to start the clinical phase I/II study CARMA in patients with B-cell lymphoma that no longer respond to standard treatment or have relapsed. “The treatment has the potential to become a very important alternative for those patients whose disease no longer respond to standard […]

The company has reported positive topline results from the ongoing Part 3 of the CORIST phase IIa colorectal cancer trial with the lead compound SCO-101. A preliminary analysis of the study data shows tumor reduction supporting combination with chemotherapy, substantially increased Progression Free Survival, high Clinical Benefit Rate and consistent safety and tolerability, states the […]

The company has announced the primary analysis of study data from Alzinova’s phase 1b clinical trial in Alzheimer’s disease with the vaccine candidate ALZ-101. The analysis confirms the top-line results and that ALZ-101 was well tolerated and safe, states the company. Furthermore, the analysis confirms a high frequency of immune response and that patients treated […]

The company has reported results from the OPTIMIZE-1 Phase 2 study of its lead asset mitazalimab in 1st line metastatic pancreatic cancer. The open-label, multi-center study assessed the safety and efficacy of mitazalimab (CD40 mAb agonist) in combination with standard of care chemotherapy mFOLFIRINOX, in previously untreated, chemotherapy naive patients. The study achieved its primary […]

The first test results from patient 1 have been received and show a very strong effect on the marker of osteoclast activity (CTX), states the company. The baseline value for CTX decreases by about 80% after 3 doses of OsteoDex. The other values are fairly constant (cf. baseline). Osteoclasts break down bone (resorb) and CTX […]

OssDsign has announced that positive data from the clinical study TOP FUSION has been submitted to a peer-reviewed scientific journal. Top-line results show a 93 % spinal fusion rate at 12 months as assessed with CT by independent radiological review from Medical Metrics Inc. after surgery with the novel nanosynthetic bone graft OssDsign Catalyst, states […]